AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Key Insights on Johnson & Johnson's Dividend Ahead of May 27, 2025 Ex-Dividend Date
Generated by AI AgentAinvest Dividend Digest
Friday, May 23, 2025 10:12 pm ET1min read
Johnson & Johnson (JNJ) has announced a forthcoming dividend of $1.300 per share, with an ex-dividend date set for May 27, 2025, and a payment date on Jun 10, 2025. This amount is notably higher compared to the average of the last ten dividends, which stands at approximately $0.456. The announcement was made on Apr 15, 2025. The last dividend issued by the company on Mar 4, 2025, was $1.240 per share. The consistent increase in dividend payouts reflects the company's strong financial health and commitment to returning value to shareholders.
Recently, has been actively engaged in several significant initiatives. The company expanded its efforts to support the global nursing workforce through the new social impact platform, CareCommunity. In the area of cancer research, promising new data was unveiled from its portfolio concerning hematologic malignancies and solid tumors, marking a significant step in innovative cancer treatments. Additionally, Johnson & Johnson announced the U.S. launch of the SOUNDSTAR CRYSTAL™ Ultrasound Catheter, a device designed to enhance intracardiac echocardiography imaging in cardiac ablation procedures. This development underscores the company's commitment to advancing medical technology and improving patient outcomes.
Over the past week, Johnson & Johnson has also been in the spotlight due to a favorable vote from the FDA's Oncologic Drugs Advisory Committee for its product DARZALEX FASPRO®, aimed at treating high-risk conditions. Amid these developments, the company's stock experienced a slight decline, closing at $152.51, representing a -0.44% adjustment from the previous day's close. However, analysts maintain a positive outlook, with a consensus rating of Moderate Buy and an average price target of $169.50, implying an upside potential.
In conclusion, Johnson & Johnson's recent strategic moves and robust dividend policy highlight its stable financial performance and innovative prowess. Investors should note that May 27, 2025, is the ex-dividend date, the last opportunity to purchase shares and receive the upcoming dividend. Any acquisitions after this date will not qualify for the current dividend payout.
Recently, has been actively engaged in several significant initiatives. The company expanded its efforts to support the global nursing workforce through the new social impact platform, CareCommunity. In the area of cancer research, promising new data was unveiled from its portfolio concerning hematologic malignancies and solid tumors, marking a significant step in innovative cancer treatments. Additionally, Johnson & Johnson announced the U.S. launch of the SOUNDSTAR CRYSTAL™ Ultrasound Catheter, a device designed to enhance intracardiac echocardiography imaging in cardiac ablation procedures. This development underscores the company's commitment to advancing medical technology and improving patient outcomes.
Over the past week, Johnson & Johnson has also been in the spotlight due to a favorable vote from the FDA's Oncologic Drugs Advisory Committee for its product DARZALEX FASPRO®, aimed at treating high-risk conditions. Amid these developments, the company's stock experienced a slight decline, closing at $152.51, representing a -0.44% adjustment from the previous day's close. However, analysts maintain a positive outlook, with a consensus rating of Moderate Buy and an average price target of $169.50, implying an upside potential.
In conclusion, Johnson & Johnson's recent strategic moves and robust dividend policy highlight its stable financial performance and innovative prowess. Investors should note that May 27, 2025, is the ex-dividend date, the last opportunity to purchase shares and receive the upcoming dividend. Any acquisitions after this date will not qualify for the current dividend payout.
Ainvest Dividend Digest
Sip from the stream of US stock dividends. Your income play.
Latest Articles
Crown Crafts Announces $0.08 Cash Dividend – Market Impact Analysis on the Ex-Dividend Date
Dec.12 2025
Impact of Eaton Vance California Municipal Income Trust’s $0.05 Dividend on Ex-Dividend Date
Dec.12 2025
Eaton Vance Senior Income Trust Announces $0.039 Dividend: Implications for the December 12 Ex-Dividend Date
Dec.12 2025
Gabelli Global Utility & Income Trust Announces $0.10 Dividend: Market Impact and Recovery Insights for Dec 12 Ex-Dividend Date
Dec.12 2025
OFS Credit Announces $0.115 Dividend: Market Implications on the Ex-Dividend Date of 2025-12-12
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet